As of July 2025, HOLX's current EPS stands at $2.39, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of $3.35, which marks an increase compared to its EPS of $1.85 in 2023. HOLX reported an EPS of -$0.08 for the quarterly report ending on Mar 29, 2025.
For 2024, Hologic's EPS was $3.35, an increase of 81.1% from $1.85 in 2023. For the fiscal quarter that ended on Mar 29, 2025, the per-share earnings was -$0.08, showing a 111.1% decrease from the same quarter last year. For the twelve months ending March 2025, the EPS is $2.39. For the year 2023, the yearly earnings per share was $1.85, marking a decrease of 64.3% from 2022.
During the last 12 months, Hologic has seen an EPS growth of -111.1% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of -22.8% per year for the last three years. A 10-year view shows that HOLX has seen an average EPS growth of 49.5% per year.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
ABT Abbott Laboratories | 16.39 | 133.8% | 24.5% | 29.9% |
JNJ Johnson & Johnson | 17.89 | -57.9% | -9.7% | 0.4% |
DGX Quest Diagnostics Inc | 19.9 | 2.5% | -21.1% | 4.1% |
HOLX Hologic Inc | 27.82 | 81.1% | -22.8% | N/A |
TMO Thermo Fisher Scientific Inc | 27.99 | 6.8% | -5.5% | 12.4% |
BDX Becton Dickinson & Co | 35.78 | 18.3% | -5.3% | 8% |
GE General Electric Co | 37.56 | -28.4% | N/A | N/A |
BSX Boston Scientific Corp | 76.91 | 16.7% | 22.2% | -17.9% |
All data is based on quarterly TTM periods, unless otherwise specified.